New 'Off-the-Shelf' cancer treatment trial offers hope for patients who have run out of options

NCT ID NCT06662227

Summary

This early-phase study is testing a new type of cell therapy called universal CAR-T (UWD-CD19) for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to standard treatments. The goal is to see if this 'off-the-shelf' therapy, made from donor cells instead of the patient's own, is safe and shows early signs of fighting the cancer. About 30 participants will receive the treatment once after preparatory chemotherapy and then be followed closely for safety and response for at least five years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi'an, Shaanxi, 710061, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.